P565: REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS

• Sjoerd Hermans,
• Yvette van Norden,
• Erik van Werkhoven,
• Avinash Dinmohamed,
• Peter Huijgens,
• Gert Ossenkoppele,
• Gerwin Huls,
• Bob Löwenberg,
• Thomas Pabst,
• Dimitri Breems,
• Douwe Postmus,
• Francesco Pignatti,
• Jurjen Versluis,
• Jan Cornelissen

Affiliations

Sjoerd Hermans

1 Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands

Yvette van Norden

1 Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands

Erik van Werkhoven

1 Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands

Avinash Dinmohamed

3 Netherlands Comprehensive Cancer Organisation (IKNL), Research and Development, Utrecht, The Netherlands

Peter Huijgens

3 Netherlands Comprehensive Cancer Organisation (IKNL), Research and Development, Utrecht, The Netherlands

Gert Ossenkoppele

4 Amsterdam University Medical Centers, Vrije Universiteit Medical Center, Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands

Gerwin Huls

5 University Medical Center Groningen (UMCG), Hematology, Groningen, The Netherlands

Bob Löwenberg

1 Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands

Thomas Pabst

6 Inselspital, Bern University Hospital, Department of Medical Oncology, Bern, Switzerland

Dimitri Breems

7 Ziekenhuis Netwerk Antwerpen, Hematology, Antwerpen, Belgium

Douwe Postmus

8 University of Groningen, University Medical Center Groningen, Epidemiology, Groningen, The Netherlands

Francesco Pignatti

9 European Medicines Agency, Oncology and Hematology Office, Amsterdam, The Netherlands

Jurjen Versluis

1 Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands

Jan Cornelissen

1 Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands